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Introduction
Necrotizing enterocolitis (NEC) is a severe intestinal inflammatory disease affecting neonates, with a higher incidence among premature babies. The disease is characterized by intestinal necrosis and leads to multiple organ failure 1 . The mortality rate associated with NEC ranges from 20 to 30%, with gastrointestinal sequelae such as stenosis and short bowel syndrome possibly being present in cases in which there is resolution or the need for surgical intervention 2 . The physiopathological events of the disease are still unknown, but their origin appears to be multifactorial.
Prematurity, bacterial infection, intestinal hypoxia-ischemia and enteral feeding are the major risk factors of the disease 3 .
In severe cases of NEC, in addition to intestinal involvement there is a frequent occurrence of injury to one or more organs resulting in pulmonary, renal and/or hepatic failure 4 .
Studies have reported significant pathological changes in hepatic morphology and in hepatobiliary function in patients with NEC, especially those submitted to parenteral nutrition 5 .
In the experimental NEC model created by Barlow and Santulli 6 and later modified by Caplan et al. 7 , the disease is induced by using enteral formula feeding associated with intermittent episodes of hypoxia and hypothermia. The elucidation of physiopathological mechanisms and the discovery of a treatment or method for an early diagnosis of NEC have been a challenge in the hope to reduce the high morbidity and mortality rates of the disease. In this respect, finding markers of tissue injury that may correlate with the disease could be of benefit for these patients. Thus, the objective of the present study was to determine the expression of L-FABP in the liver and compare it to the expression of I-FABP in the intestine of newborn rats submitted to the experimental NEC model.
Methods
The project was approved by the Ethics Committee for 
Experimental groups
All pups were weighed at birth and allotted at random to two experimental groups: Control (C), in which the animals were not manipulated and were suckled by their respective dams, and Necrotizing Enterocolitis (NEC), in which the pups were removed from their dams immediately after birth, weighed daily, fed artificial Esbilac® milk (PetAg, Hampshire, IL, USA) (~200 kcal/kg/day) and subjected to an ischemia/hypothermia protocol twice a day for a total of six days until sacrifice.
These groups were divided into two subgroups (n=4): collection 1 (animals sacrificed after the first ischemia/ hypothermia process) -groups C1 and NEC1, and collection 6
(animals sacrificed after 6 ischemia/hypothermia processes) -groups C6 and NEC6. Control groups C1 and C6 were sacrificed at the same times as the experimental groups but were not submitted to any procedure.
Surgical procedure
The pups were weighed and sacrificed by decapitation.
After laparotomy, the liver and ileum were collected, weighed and fixed in 10% buffered formol.
Morphometric evaluation
Body weight (BW), liver weight (LW), intestinal weight 
Statistical analysis
Morphology and molecular biology data were analyzed by one-way ANOVA followed by the Tukey-Kramer post-test and immunohistochemical data were analyzed by the Kruskal-Wallis test followed by the Dunn post-test, with the level of significance set at p<0.05. Data are reported as mean ± standard deviation. All analyses were carried out using the GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, USA).
Results

Morphometric analysis
Evaluation of BW revealed weight gain in the pups of the Control group (C), with a significant difference between C1 and C6 (p<0.001). BW was significantly reduced in the NEC6 group compared to C1 (p<0.001), to C6 (p<0.001) and to NEC1 (p<0.001).
LW was reduced in group NEC6 compared to C1, C6 and NEC1 (p<0.001). IW was increased in group C6 compared to groups C1, NEC1 and NEC6 (p<0.001). The LW/BW ratio was reduced in group C6 compared to groups C1 and NEC1 (p<0.001). There was also a reduction in group NEC1 compared to C1 (p<0.05) and in group NEC6 compared to C1 and NEC1 (p<0.001). The IW/BW ratio was increased in group C6 compared to groups C1 and NEC1 (p<0.001) and also in group NEC6 compared to groups C1, NEC1
and C6 (p<0.001, p<0.001 and p<0.05, respectively) ( Table 1) .
Immunohistochemical analysis
Immunohistochemical study of L-FABP expression revealed increased protein labeling in group C6 compared to group NEC1 (p<0.001). On the other hand, there was a significant reduction (p<0.001) of expression in group NEC6 compared to groups C1, C6 and NEC1 (p<0.001) (Figure 1 ). Intestinal I-FABP labeling was increased in group NEC6 compared to the other three groups (p<0.001) (Figure 2 ).
Western blotting analysis
The evaluation of L-FABP expression by Western blotting revealed an increase in group C6 compared to groups C1 and NEC1 (p<0.001). Conversely, there was a reduction of density in group NEC6 compared to groups C1, C6 and NEC1 (p<0.05, p<0.001 and p<0.001, respectively). In the ileum there was an increase in I-FABP expression in group NEC1 compared to group C1 (p<0.001), as well as in group C6 compared to groups C1 (p<0.001) and NEC1 (p<0.001). In group NEC6 there was an increase in I-FABP expression compared to the other three groups (p<0.001) (Figure 3 ). has not been fully clarified, but prematurity, intestinal ischemia, bacterial colonization and enteral feeding are factors hat favor the development of the disease 3 . In the present study, we used as an experimental model the protocol of ischemia and hypothermia associated with enteral formula feeding.
Groups
Morphometric analysis revealed a considerable impact of artificial milk feeding on the evolution of BW, with a significant reduction in the groups fed Esbilac® artificial milk for a longer period of time. Several other studies using similar milk formulas also reported a weight loss 9, 10 .
There was a reduction of LW in the group receiving formula, although the NEC6 group showed significant liver involvement compared to groups C1, C6 and NEC1. The pups submitted to the protocol showed varying degrees of inflammation in the intestinal loops, with NEC6 also showing IW loss. Since the portal vein drains the blood circulation from the intestine directly into the liver, the proinflammatory cytokines originating from the intestinal loops are believed to also cause an inflammatory reaction in the liver, with a deleterious effect on LW
11
. The LW/BW ratio was lower in the NEC6 group than in the C1, C6 and NEC1 groups.
Although we did not determine tissue or serum cytokines, we may infer that there was liver damage as a consequence of the intestinal inflammatory process, which also explained the reduction of the IW/BW ratio mainly in the NEC6 group 11 .
Several studies have described the applicability of the L-FABP protein to the detection of hepatic injury in diseases such as hepatocellular adenoma 12 and chronic HCV infection 13 .
In addition, I-FABP has already been studied in experimental and clinical NEC models 14 . In the present study we observed reduced L-FABP labeling in the immunohistochemistry of liver tissue and in Western blotting in pups submitted to the NEC protocol.
Memon et al. 15 During infectious and inflammatory processes, the host response is characterized by various infectious changes in lipid metabolism such as increased lipogenesis and fatty acid re-esterification in the liver and inhibition of hepatic fatty acid oxidation 16, 17 . Since L-FABP acts on fatty acid metabolism, it may In addition, this hypothesis is supported by studies that have correlated L-FABP with other inflammatory liver diseases.
High serum concentrations of this protein have been detected in patients with chronic hepatitis C and with non-alcoholic fatty liver disease, with the quantity of the molecule showing a good correlation with the degree of hepatic inflammation in both cases 13 .
In the present study we compared these results with I-FABP expression in the intestine. The expression of this protein was inverse to that of L-FABP, i.e., it was increased mainly in NEC6 and, for the same reason, we believe that this was due to the inflammatory process. After enterocyte rupture, I-FAPB is released into the bloodstream and, due to this high expression, its serum level is increased. All analyses were carried out on intact bowels.
Conclusion
The hepatic expression of L-FABP is altered in NEC and that this result is inverse to the expression of I-FABP detected in the intestine, data that could contribute to the use of FABPs for a better diagnosis and an improvement of the severity of NEC in affected neonates.
